[1] |
Bosch FX, Ribes J, Cléries R, et al. Epidemiology of hepatocellular carcinoma[J]. Clin Liver Dis, 2005, 9(2): 191-211.
|
[2] |
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-1255.
|
[3] |
Taketomi A, Kitagawa D, Itoh S, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients[J]. J Am Coll Surg, 2007, 204(4):580-587.
|
[4] |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
|
[5] |
Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis[J]. Eur J Cancer, 2010, 46(6): 1056-1061.
|
[6] |
Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future[J]. Semin Cancer Biol, 2011, 21(1): 59-69.
|
[7] |
Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies[J]. Somatic Cell Genet, 1979, 5(6): 957-971.
|
[8] |
聂凯,薛小军,张文华,等.血清CEA、CA19-9联合检测在肝内胆管结石合并肝内胆管细胞癌诊断中的价值[J/CD].中华肝脏外科手术学电子杂志,2015,4(4):215-217.
|
[9] |
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment[J]. Hepatology, 2008, 48(1): 308-321.
|
[10] |
Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases[J]. Cancer, 1988, 61(10): 2100-2108.
|
[11] |
Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007[J]. Int J Cancer, 2016, DOI: 10.1002/ijc.30211[Epub ahead of print].
|
[12] |
Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus[J]. Semin Liver Dis, 2006, 26(2): 153-161.
|
[13] |
Li J, Zhou J, Yang PH, et al. Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma[J]. Eur J Cancer, 2016(62): 86-95.
|
[14] |
余剑英, 黄柏英.血清CA125、CA199对肝硬化和肝癌的诊断价值[J].中国医师杂志,2004,6(2): 266-267.
|
[15] |
郭红梅.血清CA199在肝硬化与肝癌诊断中的价值[J].放射免疫学杂志,2003,16(4): 207-208.
|
[16] |
谭政良,雷萌.肝病患者血清糖类抗原CA199化学发光法检测的临床意义[J].中国现代医学杂志,2003,13(10):67-68.
|
[17] |
Yu L, Zhang BF, Cheng ML, et al. Quantitative assessment of mutations in hepatitis B virus genome with liver cirrhosis and hepatocellular carcinoma development[J]. Oncotarget, 2016, DOI: 10.18632/oncotarget.9417[Epub ahead of print].
|
[18] |
Wilson EM, Tang L, Kottilil S. Eradication strategies for chronic hepatitis B infection[J]. Clin Infect Dis, 2016, 62 Suppl 4: S318-325.
|
[19] |
Tarao K, Rino Y, Takemiya S, et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma[J]. Intervirology, 2000, 43(1): 20-26.
|
[20] |
Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update[J]. Liver Int, 2005, 25(3): 472-489.
|
[21] |
Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA[J]. Ann Clin Biochem, 1998, 35 (Pt 1): 99-103.
|